Compare prices and buy Livagen from 4 research peptide vendors - also called suppliers or sources. Updated daily.
A synthetic tetrapeptide (Lys-Glu-Asp-Ala / KEDA) in the Khavinson short-peptide family, associated with liver tissue. Russian preclinical studies report hepatoprotective effects in animal and cell models of liver injury, and loosening of tightly packed chromatin in cultured lymphocytes from elderly donors. Part of the Cytogen class. It has no FDA approval.
For research purposes only. Not medical advice.
Livagen is a synthetic tetrapeptide, Lys-Glu-Asp-Ala (written KEDA), from Vladimir Khavinson's short-peptide program. The rest of the family is in Longevity and Bioregulators. A 2001 paper by the group describes it as synthesized from an amino acid analysis of liver polypeptide preparations. PubChem's compound record for Lys-Glu-Asp-Ala, which carries the name Livagen, gives the formula C18H31N5O9 and a molecular weight of about 461.5.
Its first three residues match Vesugen, and the same prefix opens Pancragen, Testagen and Prostamax. All are separate compounds.
The group's 2022 review in the International Journal of Molecular Sciences lists Livagen as KEDA and labels it a hepatoprotector, as it does Ovagen. For Livagen it cites a 2020 Russian-language review by Kuznik, Khavinson and colleagues, which summarizes animal and in-vitro studies of the tetrapeptide, and of Ventvil, a polypeptide complex from liver, in models of liver disease that include acute and chronic hepatitis (Advances in Gerontology, 2020).
The developers' US patent, US 7,101,854, granted in 2006 with Khavinson as inventor, claims the tetrapeptide and describes it as stimulating the functional activity of liver cells.
Every study below lists Khavinson as an author or inventor, and all of them are animal or laboratory work.
All of it is laboratory work on blood cells taken from donors.
PeptideScouter found one report describing patients, in the 2006 US patent. It describes 23 patients aged 32 to 53 with chronic persistent hepatitis who received the peptide for 10 to 40 days, and reports lower bilirubin and alanine aminotransferase, a liver enzyme, after treatment than before. Its results tables compare the treated patients before and after treatment and give no figures for the 12 conventionally treated patients it names as a control group.
A PubMed search by name and by sequence in October 2026 found no study in which people received the peptide.
PeptideScouter found no US regulatory record for Livagen. As of October 22, 2026, it appears in none of these:
Only in one report PeptideScouter could find, and it is not a registered trial. The developers' 2006 US patent describes 23 patients with chronic persistent hepatitis who received the tetrapeptide Lys-Glu-Asp-Ala and reports lower bilirubin and alanine aminotransferase levels after treatment than before. It names a control group of 12 conventionally treated patients but gives no figures for it. ClinicalTrials.gov lists no study of the peptide as of October 2026, and the chromatin studies on Livagen were laboratory work on blood cells from older donors.
They are its developers' animal and cell studies. Their 2006 US patent reports that in rats poisoned with carbon tetrachloride, the tetrapeptide Lys-Glu-Asp-Ala was followed by milder liver damage, and that when given after the exposure it returned blood protein, bilirubin, cholesterol and liver enzymes to normal values. A 2001 study reported that it raised protein synthesis in cultured rat liver cells, most strongly in cells from old animals. Vladimir Khavinson's group labels it a hepatoprotector in a 2022 review, citing a 2020 review of animal and in-vitro liver studies. PeptideScouter found no controlled trial of it in people.
PeptideScouter found no US regulatory record for it. As of October 22, 2026, Livagen does not appear in Drugs@FDA, in either table of FDA's Category 2 list of bulk drug substances raising significant safety risks, in FDA's lists of substances nominated for compounding under Sections 503A and 503B, or among the substances FDA named for its July 2026 and next Pharmacy Compounding Advisory Committee meetings. FDA's substance registry has no record of it, ClinicalTrials.gov lists no study of it and no FDA warning letter names it.
PeptideScouter lists none. PubChem's compound record for Lys-Glu-Asp-Ala, the Livagen sequence, gives the formula C18H31N5O9 and a molecular weight of about 461.5, and shows a CAS-format number only among synonyms supplied by depositors, not in its CAS identifier section. FDA's substance registry has no record of the peptide. Without a registry-backed CAS number, the sequence and formula are what a certificate of analysis can be checked against.
Livagen is sold by 4 research peptide vendors indexed on PeptideScouter, with 4 tracked listings compared per vendor in the table above. Pricing is normalized and refreshed daily.
All 4 indexed research peptide vendors currently have Livagen in stock. Stock state is refreshed daily from each vendor's catalog.
Glow Aminos currently lists Livagen at $2.07/mg, the lowest listed price across 4 tracked research peptide vendors. With current vendor discount codes applied, the lowest effective price is $1.76/mg.
Discount codes are issued per vendor rather than per peptide, so any code applies across that vendor's whole catalog. All 4 vendors listing Livagen publish a PeptideScouter code, worth 10% to 15% off. Applied, the lowest effective price falls from $2.07/mg listed to $1.76/mg at Glow Aminos. Each vendor's code is shown beside its price in the table above.
Livagen ranges from $2.07/mg to $3.15/mg across 4 listings from 4 research peptide vendors, normalized to USD per milligram and refreshed daily.
4 research peptide vendors currently list Livagen on PeptideScouter. We track 4 listings across size and kit variants.
